BioCentury | Jan 29, 2021
Management Tracks

Bilenker leaving Lilly’s Loxo; plus updates from Orchard, Genfit, OncXerna, Medable, Neurophth, Elevian, Biofidelity, BIO

...SVP of regulatory affairs. She was chief development officer and head of regulatory and quality at Partner Therapeutics Inc....
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...has resigned as CEO and chairman and will transition to an advisory role. Edwin Rock joined cancer company Partner Therapeutics Inc....
...was president and CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Partner Therapeutics Inc. Brii...
BioCentury | Aug 6, 2020
Product Development

Warp Speed makes J&J COVID-19 vaccine program fifth above $1B

...ventilation (see “Second IL-6 Failure” ; “Data for IL-6 mAb in COVID-19 Disappoint” ). Separately, Partner Therapeutics Inc....
...stimulating factor (GM-CSF)) U.S. Biomedical Advanced Research and Development Authority U.S. Department of Defense Johnson & Johnson Regeneron Pharmaceuticals Inc. Sanofi Partner Therapeutics Inc. SARS-CoV-2...
BioCentury | Nov 9, 2019
Company News

Management tracks: Teva, Ipsen, ADC, Assembly, Kaleido, Biodesix, CorMedix, Ideaya, Partner, Neurana, Odylia and T1D Exchange

...general counsel at NeoTract Inc. prior to its acquisition by Teleflex Inc. (NYSE:TFX). Cancer company Partner Therapeutics...
...S.A. ADC Therapeutics S.A. Relay Therapeutics Inc. Biodesix Inc. Odylia Therapeutics Inc. Kaleido Biosciences Inc. CorMedix Inc. T1D Exchange Neurana Pharmaceuticals Inc. Assembly Biosciences Inc. Partner Therapeutics Inc. Teva...
BioCentury | May 25, 2018
Company News

Management tracks: ISA, ImCheck, ArQule

...company ImCheck Therapeutics S.A.S. (Marseille, France) appointed Debasish Roychowdhury as chairman. He is CMO at Partner Therapeutics Inc....
BioCentury | Feb 26, 2018
Company News

Management tracks: Vertex, Basilea

...He was SVP and head of early clinical development at Pfizer Inc. (NYSE:PFE). Cancer company Partner Therapeutics Inc....
BioCentury | Feb 2, 2018
Financial News

Partner Therapeutics raises $60M, in-licenses Leukine

...Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Thursday in a series A round led by...
...to use this initial financing to acquire a cancer-focused portfolio of approved and late-stage therapies. Partner Therapeutics'...
...Partner Therapeutics gained exclusive, worldwide rights to develop, manufacture and commercialize cancer drug Leukine from Sanofi. Partner Therapeutics...
BioCentury | Feb 2, 2018
Company News

Partner Therapeutics raises $60M, in-licenses Leukine

...Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Feb. 1 in a series A round led...
...Partner Therapeutics gained exclusive, worldwide rights to develop, manufacture and commercialize cancer drug Leukine from Sanofi. Partner Therapeutics...
...a March 29 PDUFA date. Partner Therapeutics Inc., Boston, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Cancer Jennie Walters Partner Therapeutics Inc.SanofiRocheSeragonMerrimack...
BioCentury | Jan 26, 2018
Company News

Management tracks: Partner Therapeutics, Merck

...Robert Mulroy and Debasish Roychowdhury launched newco Partner Therapeutics Inc. (Boston, Mass.), which has a portfolio of approved...
BioCentury | Jul 5, 2004
Tools & Techniques

ARD makes cells go 'round

Arresting or otherwise controlling the cell cycle, especially in cancer tissue, is a strategy used by many chemotherapeutics. Brandeis University researchers are elucidating the role of aci-reductone dioxygenases (ARDs) in cell division and believe the...
Items per page:
1 - 10 of 15
BioCentury | Jan 29, 2021
Management Tracks

Bilenker leaving Lilly’s Loxo; plus updates from Orchard, Genfit, OncXerna, Medable, Neurophth, Elevian, Biofidelity, BIO

...SVP of regulatory affairs. She was chief development officer and head of regulatory and quality at Partner Therapeutics Inc....
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...has resigned as CEO and chairman and will transition to an advisory role. Edwin Rock joined cancer company Partner Therapeutics Inc....
...was president and CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Partner Therapeutics Inc. Brii...
BioCentury | Aug 6, 2020
Product Development

Warp Speed makes J&J COVID-19 vaccine program fifth above $1B

...ventilation (see “Second IL-6 Failure” ; “Data for IL-6 mAb in COVID-19 Disappoint” ). Separately, Partner Therapeutics Inc....
...stimulating factor (GM-CSF)) U.S. Biomedical Advanced Research and Development Authority U.S. Department of Defense Johnson & Johnson Regeneron Pharmaceuticals Inc. Sanofi Partner Therapeutics Inc. SARS-CoV-2...
BioCentury | Nov 9, 2019
Company News

Management tracks: Teva, Ipsen, ADC, Assembly, Kaleido, Biodesix, CorMedix, Ideaya, Partner, Neurana, Odylia and T1D Exchange

...general counsel at NeoTract Inc. prior to its acquisition by Teleflex Inc. (NYSE:TFX). Cancer company Partner Therapeutics...
...S.A. ADC Therapeutics S.A. Relay Therapeutics Inc. Biodesix Inc. Odylia Therapeutics Inc. Kaleido Biosciences Inc. CorMedix Inc. T1D Exchange Neurana Pharmaceuticals Inc. Assembly Biosciences Inc. Partner Therapeutics Inc. Teva...
BioCentury | May 25, 2018
Company News

Management tracks: ISA, ImCheck, ArQule

...company ImCheck Therapeutics S.A.S. (Marseille, France) appointed Debasish Roychowdhury as chairman. He is CMO at Partner Therapeutics Inc....
BioCentury | Feb 26, 2018
Company News

Management tracks: Vertex, Basilea

...He was SVP and head of early clinical development at Pfizer Inc. (NYSE:PFE). Cancer company Partner Therapeutics Inc....
BioCentury | Feb 2, 2018
Financial News

Partner Therapeutics raises $60M, in-licenses Leukine

...Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Thursday in a series A round led by...
...to use this initial financing to acquire a cancer-focused portfolio of approved and late-stage therapies. Partner Therapeutics'...
...Partner Therapeutics gained exclusive, worldwide rights to develop, manufacture and commercialize cancer drug Leukine from Sanofi. Partner Therapeutics...
BioCentury | Feb 2, 2018
Company News

Partner Therapeutics raises $60M, in-licenses Leukine

...Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Feb. 1 in a series A round led...
...Partner Therapeutics gained exclusive, worldwide rights to develop, manufacture and commercialize cancer drug Leukine from Sanofi. Partner Therapeutics...
...a March 29 PDUFA date. Partner Therapeutics Inc., Boston, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Cancer Jennie Walters Partner Therapeutics Inc.SanofiRocheSeragonMerrimack...
BioCentury | Jan 26, 2018
Company News

Management tracks: Partner Therapeutics, Merck

...Robert Mulroy and Debasish Roychowdhury launched newco Partner Therapeutics Inc. (Boston, Mass.), which has a portfolio of approved...
BioCentury | Jul 5, 2004
Tools & Techniques

ARD makes cells go 'round

Arresting or otherwise controlling the cell cycle, especially in cancer tissue, is a strategy used by many chemotherapeutics. Brandeis University researchers are elucidating the role of aci-reductone dioxygenases (ARDs) in cell division and believe the...
Items per page:
1 - 10 of 15